CELLCEUTIX CORPORATION (OTCMKTS:CTIX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On March 27, 2017 Cellceutix Corporation issued a press release
titled Cellceutix Reports Very Encouraging Interim
Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral
Mucositis (OM) in Head and Neck Cancer Patients; High Potential
for Preventative Treatment
A copy of the press release is furnished herewith as Exhibit
99.1.
The information in this Current Report on Form 8-K under Item
2.02, including the accompanying press release, shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, except as shall be expressly set forth by
reference to such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNo. |
Description |
|
99.1 |
Press Release dated March 27, 2017. |
About CELLCEUTIX CORPORATION (OTCMKTS:CTIX)
Cellceutix Corporation (Cellceutix) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies with oncology, dermatology and antimicrobial applications. Cellceutix owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics. The Company’s clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Prurisol for the treatment of psoriasis, and Brilacidin for treatments of skin infections, prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis. The Company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics and inflammatory disease. Kevetrin is a small molecule compound that induces activation of p53. CELLCEUTIX CORPORATION (OTCMKTS:CTIX) Recent Trading Information
CELLCEUTIX CORPORATION (OTCMKTS:CTIX) closed its last trading session up +0.05 at 1.00 with 176,948 shares trading hands.